Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions reference the positive outcomes related to dupilumab, such as reduced exacerbation rates and improved lung function, which users describe as a 'glimmer of hope' for patients with COPD. Phrases like 'game changer' and 'hope for our COPD patients' reflect the excitement and urgency in the conversations, which, along with the supportive tone, contribute to a perception that this publication could significantly alter therapeutic approaches.
The majority of discussions indicate strong support for the findings of the publication, highlighting its significance.
Users exhibit a high level of curiosity, discussing results and implications of dupilumab for treating COPD.
While some participants engage deeply, providing context and insights, others display a more surface-level interaction.
There is a consensus that this research has a significant influence on the treatment landscape for COPD.
Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YYil Editorial: Biologics for COPD — Finally Here https://t.co/hBn6tmaAfP #ATS2023
Yesterday’s 2nd pos Phase 3 for Dupi in COPD… real hero was power of human genetics showing IL-4/IL-13 associations with COPD. Same happening with IL-33. Now COPD could be “opened” for Rx intervention. Genetics can drive CONVICTION in making big bets. https://t.co/0TKseG3lcW
A glimmer of hope for our COPD Patients
Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new RX for COPD + eosinophilia excluded age >80 Ageist Inexcusable Once again NEJM publishes without even noting this as limitation https://t.co/Pe7oJ2KNet
好酸球数300以上のCOPDにおいてデュピルマブはプラセボに対して増悪頻度を有意に減少した New England Journal of Medicine https://t.co/ECBsfJ7GNC
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. July 20, 2023 https://t.co/CJ3AIRPNNo https://t.co/xIGbIyLPpn
This video discusses a phase 3 trial that explored dupilumab's effects on COPD patients with high eosinophil counts. Results indicated significant reductions in exacerbation rates and improvements in lung function and…
Stephanie Sudikoff discusses expanding treatment for neonatal jaundice through medical simulation for healthcare professionals. The conversation also highlights recent findings on dupilumab's effectiveness in reducing…
#AulasAbiertasUdeA | Dupilumab for COPD with Type 2: Inflammation Indicated by Eosinophil Counts - Dr. Edwin de la Peña
BOREAS試験・NOTUS試験（Eos300以上のCOPD患者へデュピルマブ投与）、プラセボと比較して年間増悪率が有意に低下し、FEV1も改善を認めた。 https://t.co/iTVhj2a3Px https://t.co/Iyi9bIRfQq
So the answer is Dupilumab! For more, read here - https://t.co/KmdIocJ5zo
https://t.co/3KUqlryBVT https://t.co/5duX3Zm9ez
Phase 3 NOTUS study in NEJM, published May 2024 https://t.co/4EvSb9zxon $SNY $REGN
Phase 3 BOREAS study in NEJM: https://t.co/4EvSb9zxon $SNY $REGN
RT @NYULangonePCCSM: Our fellows recently discussed biologic therapy for #Asthma and #COPD at journal club! Check out what our fellows are…
Our fellows recently discussed biologic therapy for #Asthma and #COPD at journal club! Check out what our fellows are reading this week
NOTUS en el 2º ensayo clínico fase III de Dupilumab en #EPOC, que confirma los resultados encontrados en el estudio BOREAS publicado el año pasado https://t.co/b5EkmRNfwK
RT @KaminskiMed: Wow. Another superb COPD study just in time for #ATS2024 - Patients with COPD & elevated blood eosinophil treated with D…
RT @KaminskiMed: Wow. Another superb COPD study just in time for #ATS2024 - Patients with COPD & elevated blood eosinophil treated with D…
RT @KaminskiMed: Wow. Another superb COPD study just in time for #ATS2024 - Patients with COPD & elevated blood eosinophil treated with D…
RT @KaminskiMed: Wow. Another superb COPD study just in time for #ATS2024 - Patients with COPD & elevated blood eosinophil treated with D…
Wow. Another superb COPD study just in time for #ATS2024 - Patients with COPD & elevated blood eosinophil treated with Dupilumab have ⬇️ exacerbations, better lung function & quality of life, less severe respiratory symptoms #CureCOPD https://t.co/CbjnUUBzMe https://t.co/iaH3QnlEEs
Link al BOREAS Trial
RT @DrAkhilRaghavan: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts Dupilumab, a fully human monoclonal antibo…
RT @ProfHurst: 4⃣ I'm a clinical researcher so forgive me moving closer to people living with COPD for my next choice. ✅*YES* there is new…
RT @ProfHurst: 4⃣ I'm a clinical researcher so forgive me moving closer to people living with COPD for my next choice. ✅*YES* there is new…
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. July 20, 2023 https://t.co/CJ3AIRPNNo https://t.co/xIGbIyLPpn
4⃣ I'm a clinical researcher so forgive me moving closer to people living with COPD for my next choice. ✅*YES* there is new hope for biologics in COPD! We've not seen data from that press release but here is the @NEJM paper by @suryapbhatt on dupliumab: https://t.co/fMBn8Q3326
RT @suryapbhatt: Great results from the NOTUS trial, replicating BOREAS (https://t.co/nfHniS0pvU). Dupilumab decreases exacerbation frequen…
RT @JMaraganore: Yesterday’s 2nd pos Phase 3 for Dupi in COPD… real hero was power of human genetics showing IL-4/IL-13 associations with C…
RT @JMaraganore: Yesterday’s 2nd pos Phase 3 for Dupi in COPD… real hero was power of human genetics showing IL-4/IL-13 associations with C…
RT @JMaraganore: Yesterday’s 2nd pos Phase 3 for Dupi in COPD… real hero was power of human genetics showing IL-4/IL-13 associations with C…
RT @JMaraganore: Yesterday’s 2nd pos Phase 3 for Dupi in COPD… real hero was power of human genetics showing IL-4/IL-13 associations with C…
Yesterday’s 2nd pos Phase 3 for Dupi in COPD… real hero was power of human genetics showing IL-4/IL-13 associations with COPD. Same happening with IL-33. Now COPD could be “opened” for Rx intervention. Genetics can drive CONVICTION in making big bets. https://t.co/0TKseG3lcW
RT @suryapbhatt: Great results from the NOTUS trial, replicating BOREAS (https://t.co/nfHniS0pvU). Dupilumab decreases exacerbation frequen…
RT @suryapbhatt: Great results from the NOTUS trial, replicating BOREAS (https://t.co/nfHniS0pvU). Dupilumab decreases exacerbation frequen…
RT @suryapbhatt: Great results from the NOTUS trial, replicating BOREAS (https://t.co/nfHniS0pvU). Dupilumab decreases exacerbation frequen…
RT @suryapbhatt: Great results from the NOTUS trial, replicating BOREAS (https://t.co/nfHniS0pvU). Dupilumab decreases exacerbation frequen…
RT @drlaurajane: It’s the BOREAS study - dupilimab for #COPD with type 2 inflammation presented by @MonaBafadhel https://t.co/e6RQEQ3PuP #B…
RT @drlaurajane: It’s the BOREAS study - dupilimab for #COPD with type 2 inflammation presented by @MonaBafadhel https://t.co/e6RQEQ3PuP #B…
RT @drlaurajane: It’s the BOREAS study - dupilimab for #COPD with type 2 inflammation presented by @MonaBafadhel https://t.co/e6RQEQ3PuP #B…
RT @drlaurajane: It’s the BOREAS study - dupilimab for #COPD with type 2 inflammation presented by @MonaBafadhel https://t.co/e6RQEQ3PuP #B…
It’s the BOREAS study - dupilimab for #COPD with type 2 inflammation presented by @MonaBafadhel https://t.co/e6RQEQ3PuP #BTSWinter2023 #RespEd
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @GCessak: Wyniki bad. klinicznego fazy III: wśród pacjentów z przewlekłą obturacyjną chorobą płuc (POChP), osoby otrzymujące przeciwciał…
Wyniki bad. klinicznego fazy III: wśród pacjentów z przewlekłą obturacyjną chorobą płuc (POChP), osoby otrzymujące przeciwciało monoklonalne Dupilumab miały mniej zaostrzeń choroby, lepszą czynność płuc i słabiej nasilone objawy chorób układu oddechowego. https://t.co/o1WlVFqbIX
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
The asthma community developed endotypes a decade ago based on clinical phenotypes. Another example is dupilumab for COPD with Type 2 inflammation. https://t.co/3BdRAiAz7h
RT @UABHeersink: Congratulations to Dr. Bhatt, winner of the Heersink School of Medicine's Featured Discovery, for his lab study "Dupilumab…
RT @UABHeersink: Congratulations to Dr. Bhatt, winner of the Heersink School of Medicine's Featured Discovery, for his lab study "Dupilumab…
Congratulations to Dr. Bhatt, winner of the Heersink School of Medicine's Featured Discovery, for his lab study "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts”. Learn more: https://t.co/bJipQbqYpN https://t.co/XzSsh3XhbC
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
https://t.co/fwrmvQcxK0
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/KP3qrMs0QW
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
RT @geri_doc: Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new…
Did you know persons over age 80 dont get COPD? Well I didn't either COPD VERY common in older persons Yet study of novel new RX for COPD + eosinophilia excluded age >80 Ageist Inexcusable Once again NEJM publishes without even noting this as limitation https://t.co/Pe7oJ2KNet
El BOREAS Trial es el primer estudio positivo con un biológico (Dupilumab) en EPOC y eosinofilia (inflamación tipo 2) y que conocimos en #ATS2023: #COPD Estudio original:
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts https://t.co/yODn3MRnXH NEWS: https://t.co/wOjxp7c6TU
RT @RFalfanV: #Dupilumab for #COPD with Type 2 Inflammation Indicated by #Eosinophil Counts | NEJM https://t.co/Vbw77oTrTW
RT @RFalfanV: #Dupilumab for #COPD with Type 2 Inflammation Indicated by #Eosinophil Counts | NEJM https://t.co/Vbw77oTrTW
RT @RFalfanV: #Dupilumab for #COPD with Type 2 Inflammation Indicated by #Eosinophil Counts | NEJM https://t.co/Vbw77oTrTW
RT @RFalfanV: #Dupilumab for #COPD with Type 2 Inflammation Indicated by #Eosinophil Counts | NEJM https://t.co/Vbw77oTrTW
#Dupilumab for #COPD with Type 2 Inflammation Indicated by #Eosinophil Counts | NEJM https://t.co/Vbw77oTrTW
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/RSZrfLHv0f
#論文 NEJM 末梢血好酸球上昇を伴う重症COPDでは、デュプリムマブの使用は急性増悪の低下と関連していた。 moderate or severe exacerbations was 0.78 (95% confidence interval [CI], 0.64 to 0.93) with dupilumab https://t.co/HKbJMJ7Tbk
RT @RevistaMFSamfyc: Dupilumab en EPOC con inflamación tipo 2 indicada por el recuento de eosinófilos https://t.co/NLMwgBoXO6 PMID 37272521
RT @alfonso_casi: Dupilumab para EPOC con inflamación tipo 2 indicado por recuentos elevados d eosinófilos en sangre: los que recibieron du…
Dupilumab para EPOC con inflamación tipo 2 indicado por recuentos elevados d eosinófilos en sangre: los que recibieron dupilumab tuvieron menos exacerbaciones, mejor función pulmonar y calidad d vida, y síntomas respiratorios menos graves que los d placebo https://t.co/nmpqcFMgMC
RT @keinakashima1: 好酸球数300以上のCOPDにおいてデュピルマブはプラセボに対して増悪頻度を有意に減少した New England Journal of Medicine https://t.co/ECBsfJ7GNC
Dupilumab en EPOC con inflamación tipo 2 indicada por el recuento de eosinófilos https://t.co/NLMwgBoXO6 PMID 37272521
好酸球数300以上のCOPDにおいてデュピルマブはプラセボに対して増悪頻度を有意に減少した New England Journal of Medicine https://t.co/ECBsfJ7GNC
#論文 血中好酸球数の上昇によって示唆される2型炎症を伴ったCOPD患者のうち、デュピルマブを受けた患者はプラセボを受けた患者に比べて急性増悪が少なく、肺機能と生活の質が良好で、重篤な呼吸器症状も軽かった。 https://t.co/2bJjbnRjPq
RT @SeeFisch: so, eosinophil inhibiting drugs will start to be used for COPD in those with increased eosinophils, but how to bear the OBNOX…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/K4foAq2Xip
RT @tipssovetorax: En pacientes con EPOC con inflamación tipo 2 por recuento elevado de eosinófilos en sangre, quienes recibieron dupilumab…
so, eosinophil inhibiting drugs will start to be used for COPD in those with increased eosinophils, but how to bear the OBNOXIOUS cost of $30,000 a YEAR for dupilumab! Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/TbD1m09pe7
RT @tipssovetorax: Dupilumab para EPOC con inflamación tipo 2 indicado por recuentos de eosinófilos (¿biologicos en EPOC, complemento, sust…
RT @tipssovetorax: Dupilumab para EPOC con inflamación tipo 2 indicado por recuentos de eosinófilos (¿biologicos en EPOC, complemento, sust…
RT @tipssovetorax: Dupilumab para EPOC con inflamación tipo 2 indicado por recuentos de eosinófilos (¿biologicos en EPOC, complemento, sust…
En pacientes con EPOC con inflamación tipo 2 por recuento elevado de eosinófilos en sangre, quienes recibieron dupilumab tuvieron menos exacerbaciones, mejor función pulmonar y calidad de vida, y síntomas respiratorios menos graves versus placebo 2 https://t.co/caqATk6Kkl
Dupilumab para EPOC con inflamación tipo 2 indicado por recuentos de eosinófilos (¿biologicos en EPOC, complemento, sustituto o suplemento?) @efrasanchez @mlaucho @alat https://t.co/caqATk6Kkl
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @barriere_dr: Ensuite un anticorps monoclonal pour diminuer les infections chez certains patients ayant une BPCO Phase 3 mais injection…
RT @barriere_dr: Ensuite un anticorps monoclonal pour diminuer les infections chez certains patients ayant une BPCO Phase 3 mais injection…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Some patients with chronic obstructive pulmonary disease (COPD) have elevated eosinophil counts, a marker of type 2 inflammation,…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/Ynl7vofNUE
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @lbernacer: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM those who received dupilumab had fewer ex…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM those who received dupilumab had fewer exacerbations, better lung function and quality of life, and less severe respiratory symptoms than those who received placebo https://t.co/3v1KZSGmLr
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @MedicinaSam:
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
RT @NEJM: Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YY…
Original Article: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts (BOREAS trial) https://t.co/9IWZr3YYil Editorial: Biologics for COPD — Finally Here https://t.co/hBn6tmaAfP #ATS2023
Looks interesting https://t.co/BeAuIgT23H
RT @medical_xpress: Dupilumab found to lessen disease in #COPD patients with type 2 inflammation @nejm https://t.co/lwdDSMyS9j https://t.co…
Starting with new therapy #rsjc Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Count
RT @medical_xpress: Dupilumab found to lessen disease in #COPD patients with type 2 inflammation @nejm https://t.co/lwdDSMyS9j https://t.co…
RT @medical_xpress: Dupilumab found to lessen disease in #COPD patients with type 2 inflammation @nejm https://t.co/lwdDSMyS9j https://t.co…
Dupilumab found to lessen disease in #COPD patients with type 2 inflammation @nejm https://t.co/lwdDSMyS9j https://t.co/K84U0wcUnn
RT @medical_xpress: Dupilumab found to lessen disease in #COPD patients with type 2 inflammation @nejm https://t.co/lwdDSMyS9j https://t.co…
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/MXZZURBRUf
RT @2minmed: #VisualAbstract: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts #StudyGraphics #chronicobstructive…
#VisualAbstract: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts #StudyGraphics #chronicobstructivepulmonarydiseaseCOPD https://t.co/LWeG9hD7KP https://t.co/mcrJZ2LM8Q
RT @by_the_HEY: 2型炎症反応を有する(好酸球数の上昇：300以上)COPD患者におけるデュピルマブの治療効果 Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts…
2型炎症反応を有する(好酸球数の上昇：300以上)COPD患者におけるデュピルマブの治療効果 Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/Izkp9P0kBd
RT @Hananianick: A glimmer of hope for our COPD Patients
RT @Hananianick: A glimmer of hope for our COPD Patients
RT @AdnanLiaqat_MD: Hope for our COPD patients! Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. https://t.co/Yl…
RT @Hananianick: A glimmer of hope for our COPD Patients
Hope for our COPD patients! Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. https://t.co/YlfSWTq50m
RT @Hananianick: A glimmer of hope for our COPD Patients
RT @Hananianick: A glimmer of hope for our COPD Patients
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM - https://t.co/vIRovKNnXH https://t.co/NQpgbnYLWm #TrendingNow #HotTopics #Trending #News #NewsUpdate #MyForumLink #BreakingNews
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM - https://t.co/vIRovKNnXH https://t.co/yrbyRTNJiy #TrendingNow #HotTopics #Trending #News #NewsUpdate #MyForumLink #BreakingNews
RT @Hananianick: A glimmer of hope for our COPD Patients
ATS2023に出てたやつ タイプ2炎症、AECOPD、デュピクセント Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/u6oW2Fu7BX
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM - https://t.co/vIRovKNnXH https://t.co/QjlqXHQ7H1 #TrendingNow #HotTopics #Trending #News #NewsUpdate #MyForumLink #BreakingNews
RT @Hananianick: A glimmer of hope for our COPD Patients
RT @Hananianick: A glimmer of hope for our COPD Patients
RT @Hananianick: A glimmer of hope for our COPD Patients
RT @Hananianick: A glimmer of hope for our COPD Patients
RT @Hananianick: A glimmer of hope for our COPD Patients
A glimmer of hope for our COPD Patients
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts | NEJM https://t.co/fhwQHrUX5e